Molecule of the Week
December 12, 2011
Posaconazole is an antifungal drug that was developed by Schering-Plough in the mid-2000s and is marketed under the trade names Noxafil and Posanol. It may be more effective than the older drug fluconazole, but it may also have more serious side effects, such as prolonged heart QT interval. Posaconazole is in Phase II clinical trials for treating Chagas disease, but its ultimate cost may be too high for sufferers of this disease.
More about this molecule from CAS, the most authoritative and comprehensive source for chemical information.